We selected GBM for further analysis based on the following selection criteria: (1) differential expression between cancer and adjacent normal tissues; (2) High-expression RARA-AS1 has a poor prognosis, while low-expression RARA-AS1 has a good prognosis; (3) MSI follows the same trend as OS survival and expression. This evidence concerns the gene RARA and cancer.